Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer
Evelina Miele1, Gian Paolo Spinelli1, Ermanno Miele2, Federica Tomao1, Silverio Tomao11Department of Experimental Medicine, University of Rome “Sapienza”, Rome, Italy; 2Biomedical Engineering, University of Rome Tor Vergata, Rome, ItalyAbstract: Breast cancer is the most...
Guardado en:
Autores principales: | Evelina Miele, Gian Paolo Spinelli, Ermanno Miele, Federica Tomao, Silverio Tomao |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bbcf6ea63fcb4cb1aea26ac70bf710aa |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy
por: Miele E, et al.
Publicado: (2012) -
Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
por: Giacomo Barchiesi, et al.
Publicado: (2021) -
First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel
por: Gupta N, et al.
Publicado: (2013) -
Paclitaxel-Loaded Macrophage Membrane Camouflaged Albumin Nanoparticles for Targeted Cancer Therapy
por: Cao X, et al.
Publicado: (2020) -
Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery
por: Wang YL, et al.
Publicado: (2011)